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The imidazole derivative, ketoconazole (KCZ), an orally
active antimycotic drug,1—6) inhibits the synthesis of ergos-
terol in fungal membrane, and of cholesterol in mammalian
cells.1,4,7) It inhibits adrenal steroidogenesis8) and blunts
testosterone production.9) KCZ is a competitive inhibitor of
cytochrome P450-dependent enzymes, mainly inhibiting the
enzyme activity of the cholesterol side-chain-cleavage en-
zyme and C17—20 lyase.
1,9—11) Because KCZ acts as a steroid
hormone inhibitor with differential selectivity of cytochrome
P-450 dependent enzymes, it is a therapeutic tool in the man-
agement of conditions in which it is beneficial to suppress
gonadal or adrenal hormone production,4,6,9,12—16) such as ad-
vanced hormone-refractory prostate cancer14,17,18) and Cush-
ing’s syndrome,19) respectively.
Leydig cells secrete testosterone, an essential steroid hor-
mone in male reproductive functions.20) A MA-10 mouse
Leydig tumor cell line was utilized for this study. MA-10
cells, responding to trophic hormones (LH and hCG) and
cAMP analogs, produce progesterone as the main steroid
hormone instead of testosterone.21) Moreover, the use of this
cloned cell line may avoid the presence of paracrine factors
from other testicular cells of primary cultures.22) The purpose
of the present study was to further characterize the effects of
KCZ on secretion of progesterone and cAMP production in
MA-10 cells and to determine the mechanism in vitro.
MATERIALS AND METHODS
Materials Ketoconazole, luteinizing hormone (LH), 3-
isobutyl-1-methylxanthine (IBMX), forskolin, sodium fluo-
ride, dibutyryl-adenosine-39:59-cyclic monophosphate (db-
cAMP) and all other chemicals were purchased from Sigma
Chemical Co. (St. Louis, MO, U.S.A.). Weymouth medium,
horse serum and cell culture related materials were pur-
chased from GIBCO-BRL (Grand Island, NY, U.S.A.).
Materials related to progesterone enhanced chemilumines-
cent detection were purchased from Ortho-Clinical Diagnos-
tics Inc., a Johnson & Johnson company (Rochester, NY,
U.S.A.). Materials related to the cAMP enzyme immunoas-
say (EIA) system and BIOTRAK cellular communication as-
says were purchased from Amersham Pharmacia Biotech
(Buckinghamshire, England, U.K.).
Cell Culture and Samples Detection The MA-10 cell
line was generously provided by Dr. Ing-Cherng Guo (Na-
tional Taiwan University, Taipei, Taiwan R.O.C.) and Dr.
Bon-Chu Chung (Academia Sinica, Taipei, Taiwan R.O.C.)
and has been maintained since an earlier study.21) 53105
cells/ml medium or 53104 cells/100 m l medium were plated
in 24-well plates or 96-well plates, respectively. Cells were
grown for 24 h in Weymouth medium containing 15% horse
serum. Then, the medium was aspirated and the cells were
washed with phosphate buffer saline (PBS). Chemicals
and/or KCZ were continuously added to the serum-free 
Weymouth medium at various concentrations and times.
Cells were maintained in a humidified incubator containing
5% CO2 at 37 °C. After incubation, media were collected and
progesterone concentrations and cAMP levels in each treat-
ment were determined by chemiluminescent detection and
cAMP EIA, respectively. Progesterone samples were mea-
sured by the detector, VITROS Eci, Ortho-Clinical Diagnos-
tics Inc., a Johnson & Johnson company (Rochester, NY,
U.S.A.).
Statistics All experiments, with duplicates of each treat-
ment, were repeated at least three times. Data of all experi-
ments were analyzed by analysis of variance (ANOVA), and
then the least significant difference (LSD) was used to deter-
mine the difference between treatments.
RESULTS
Dose and Time Course Effects of KCZ on Progesterone
Production in MA-10 Cells The effect of different incuba-
tion times (1, 2, 3 h) with different concentrations of KCZ (2,
20 mM) on progesterone production in MA-10 cells is shown
in Fig. 1. The progesterone levels after 20 mM KCZ treatment
were lower than those after 2 mM KCZ treatment. When incu-
bated with 20 mM KCZ, the production of progesterone de-
creased at least 6-fold compared with the basal level. Mean-
while, significant difference in progesterone production was
suppressed by KCZ compared with the basal level from 1 to
* To whom correspondence should be addressed. e-mail: d8538002@mail.nchu.edu.tw © 2002 Pharmaceutical Society of Japan
Effects of Ketoconazole on Progesterone and cAMP Production in MA-10
Mouse Leydig Tumor Cells
Cicero Lee-Tian CHANG* and Hang-Poung FUNG
Department of Veterinary Medicine, College of Veterinary Medicine, National Chung Hsing University; 250 Kuo Kuang
Road, Taichung 402, Taiwan, R.O.C. Received November 29, 2001; accepted February 13, 2002
The effects of ketoconazole (KCZ) on secretion of progesterone and cAMP in Leydig cells were investigated
in vitro. MA-10 mouse Leydig tumor cells were used to conduct the experiments. KCZ significantly inhibited the
progesterone production from MA-10 cells in a dose dependent fashion between 2 and 20 mM among 1, 2 and 3 h
of incubation. There was a statistically significant difference in luteinizing hormone (LH) stimulated proges-
terone production inhibited by 2 and 20 mM KCZ treatment compared to the control. The effect of KCZ on prog-
esterone biosynthesis in MA-10 cells was mediated by cAMP, since KCZ suppressed basal and LH stimulated
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ride on the adenylate cyclase system were also inhibited by KCZ. Moreover, dibutyryl cAMP blocked the in-
hibitory effect on steroidogenesis of KCZ in MA-10 cells. These data indicated that KCZ induced the inhibition
of a catalytic component of adenylate cyclase holoenzyme in MA-10 mouse Leydig tumor cells.
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3 h incubation, especially those values since 2 h after KCZ
treatment.
Effect of KCZ on Progesterone Production in MA-10
Cells after LH Stimulation The effect of different LH
dosages (5, 25 mg/ml) on progesterone secretion in MA-10
cells without and with KCZ incubation (2, 20 mM) is shown
in Fig. 2. Pretreatment (2 h) with 2 and 20 mM KCZ led to an
inhibition of basal progesterone secretion and also of proges-
terone secretion after stimulation with different LH dosages
(5, 25 mg/ml; Fig. 2.). Progesterone increased 80-fold (from
0.7660.05 to 61.8762.93 nmol/l) 2 h after 25 mg LH/ml
without KCZ, whereas pretreatment with 20 mM KCZ de-
creased basal and LH-stimulated progesterone production
(0.1160.02, 9.1562.90 nmol/l). This pattern was noted with
all LH and KCZ dosages.
cAMP Production and Progesterone Secretion of Rela-
tive Tests The cAMP levels corresponded to the proges-
terone production in MA-10 cells. Basal cAMP level in-
creased 1.2-fold after 5 mg LH/ml stimulation (from 3226
13 fmol/53104 cells to 393614 fmol/53104 cells) and after
inhibition of phosphodiesterase with 0.5 mM IBMX (from
2288686 fmol/53104 cells to 27956111 fmol/53104 cells).
Twenty mM KCZ pretreatment (2 h) led to a suppressed
cAMP production (227616 fmol/53104 cells and 2926
14 fmol/53104 cells) after LH and IBMX treatment (17676
41 fmol/53104 cells and 2474663 fmol/53104 cells) (Fig.
3). IBMX also increased the progesterone production, but the
values were less than those of LH stimulation. Moreover, the
elevated progesterone levels by IBMX treatment were not
significantly inhibited by 20 mM KCZ (Fig. 3). Besides the
preliminary tests, basal and LH (5 mg/ml) stimulated proges-
terone decreased with KCZ (20 mM) treatment, addition of
db-cAMP (10 mM) led to further significant increase of basal
and LH-stimulated progesterone secretion in the presence of
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Fig. 1. The Inhibitory Effect of KCZ Incubation (Basal, 2, 20 mM) on
Progesterone Production in MA-10 Cells for Different Periods (1—3 h).
MA-10 cells were incubated 24 h. Progesterone in the medium was measured by en-
hanced chemiluminescent detection. Each data point in the figure represents
mean6S.E. of progesterone production of repeated experiments with triplicates in each
treatment. Different Arabic numbers beside the lines indicates statistically significant
differences (p,0.05) among treatments.
Fig. 3. The Inhibitory Effect of KCZ Incubation (Basal, 20 mM) on cAMP
Production and Corresponding Progesterone Secretion in MA-10 Cells with
IBMX (0.5 mM) as Phosphodiesterase Inhibitor, LH (5 mg/ml) or Both for
2 h
KCZ was preincubated for 2 h. MA-10 cells were incubated 24 h. cAMP in the
medium was measured by EIA. Progesterone in the medium was measured by enhanced
chemiluminescent detection. Each data point in the figure represents mean6S.E. of
cAMP and progesterone production of repeated experiments with triplicates in each
treatment. Asterisk (*) indicates statistically significant difference (p,0.05) as com-
pared with control (without KCZ pretreatment) levels. Arabic numbers above the bars
indicates corresponding progesterone secretion. 1, 0.6260.05; 2, 61.4067.86; 3, 4.316
0.70; 4, 3.5960.80; 5, 0.0860.01; 6, 0.3660.10; 7, 4.7060.69; 8, 3.2960.45 nmol/l.
Fig. 2. The Inhibitory Effect of KCZ Incubation (Basal, 2, 20 mM) on
Progesterone Production in MA-10 Cells with Basal and LH Stimulation
(Basal, 5, 25 mg/ml for 2 h)
KCZ was preincubated for 2 h. MA-10 cells were incubated 24 h. Progesterone in the
medium was measured by enhanced chemiluminescent detection. Each data point in the
figure represents mean6S.E. of progesterone production of repeated experiments with
triplicates in each treatment. Asterisk (* ) indicates statistically significant difference
(p,0.05) as compared with control (without KCZ pretreatment) levels.




KCZ (20 mM) 0.1160.02*,a
LH (5 mg/ml) 55.6063.32*,d
LH1KCZ 2.4560.55bd
KCZ1db-cAMP (10 mM) 3.4360.41a
LH1KCZ1db-cAMP 12.8060.93b
MA-10 cells were incubated 24 h. Different compounds were added to selected wells
and aliquots of the medium were removed from well at 2 h. Progesterone in the medium
was measured by enhanced chemiluminescent detection. Each piece of data in the table
represents mean6S.E. of progesterone production of repeated experiments with tripli-
cates in each treatment. Asterisk (* ) indicates statistically significant difference
(p,0.05) as compared with control (without KCZ pretreatment) levels. Different letters
beside the values indicates statistically significant difference (p,0.05) among treat-
ments.
20 mM KCZ (Table 1). Stimulation of the catalytic subunit of
the adenylate cyclase system with 5 mM forskolin led to sig-
nificant progesterone and cAMP production, which was also
significantly inhibited by 20 mM KCZ (Table 2). Sodium fluo-
ride (1 mM) incubation which stimulated the GS protein sig-
nificantly increased progesterone production which was sig-
nificantly suppressed by 20 mM KCZ. Meanwhile, cAMP re-
leases after 1 mM sodium fluoride treatment were signifi-
cantly increased and significantly suppressed by 20 mM KCZ
(Table 2).
DISCUSSION
Our data demonstrated that KCZ inhibits secretion of
progesterone in a dose dependent fashion from 1 to 3 h in
MA-10 mouse Leydig tumor cells (Fig. 1). Similar dose-de-
pendent inhibition of progesterone synthesis by KCZ was
shown in a previous study,22) KCZ inhibited the hCG- and
db-cAMP-stimulated progesterone production from MA-10
Leydig cells by directly inhibiting the activity of cholesterol
side-chain cleavage enzyme.22) Inhibition of C17—20 lyase by
KCZ has been demonstrated by an increase in the ratio of
precursor (17a-hydroxyprogesterone or 17a ,20a-dihydroxy-
progesterone or progesterone or all) to product (androstene-
dione or testosterone) both in vivo13,16) and in vitro.23—25)
Moreover, cholesterol side-chain-cleavage blockade by KCZ
has been demonstrated in both testicular and adrenal tissue
preparations.26,27) Therefore, the significantly inhibited prog-
esterone production in MA-10 cells by KCZ corresponds to
the results of in vitro studies in rat testicular microsomes
with KCZ. It has shown that cholesterol side-chain-cleavage
has a higher sensitivity to KCZ than does C17—20 lyase.
27)
MA-10 cells released progesterone into the medium in re-
sponse to different doses of LH (Fig. 2); this release was cou-
pled with an increase of cAMP levels (Fig. 3).28) That cAMP
is the second messenger to LH stimulation of progesterone in
MA-10 Leydig tumor cells was demonstrated by the observa-
tion that added db-cAMP also led to a rise in progesterone
production. Moreover, inhibition of phosphodiesterase with
IBMX29) led to an increase in cAMP production and proges-
terone secretion.
The stimulation of the catalytic component of the adeny-
late cyclase holoenzyme with forskolin30) also induced a sig-
nificant increase in cAMP and progesterone production in
MA-10 cells. A stimulatory agent of the GS protein of adeny-
late cyclase system, like sodium fluoride,30) also led to an in-
crease in progesterone and cAMP production in MA-10
cells. KCZ suppressed basal cAMP and progesterone produc-
tion from these cells (Figs. 1—3). Basal phosphodiesterase
activity was inhibited by IBMX29) indicating that adenylate
cyclase is required to maintain progesterone biosynthesis
which is inhibited by KCZ (Fig. 3). Therefore, KCZ inhibited
progesterone secretion and cAMP production after inhibiting
of phosphodiesterase by IBMX and stimulating by different
doses of LH (Figs. 2, 3). MA-10 cells have LH/hCG recep-
tors and respond to LH/hCG and cAMP via increased pro-
duction of progesterone.21,22) KCZ decreased cAMP produc-
tion by blockading the pathway of catalytic component of the
adenylate cyclase in the present study, and was also an in-
hibitor of the cholesterol side-chain-cleavage enzyme.1—9,11)
Therefore, the significant inhibitory effect of KCZ incubation
on LH-stimulated progesterone production in MA-10 cells
was not noted in combined IBMX treatment (Fig. 3). How-
ever, the reason a lower extent of increased progesterone val-
ues did not match the higher cAMP levels after IBMX treat-
ment needs further investigation. In contrast, the hCG-stimu-
lated cAMP production was not inhibited by KCZ.22) Chaud-
hary and Stocco suggested that the locus of hCG-stimulated
progesterone synthesis was not related to cAMP production
in MA-10 cells.22) This meant that the inhibitory effects of
KCZ between progesterone and cAMP production after LH
stimulation (Figs. 2, 3) interacted in MA-10 cells. Addition
of exogenous db-cAMP to MA-10 cells pretreated with KCZ
neutralized the inhibitory effect of KCZ on progesterone pro-
duction in the basal state and after LH stimulation (Table 1).
Stimulation of the GS protein of the adenylate cyclase system
by sodium fluoride was suppressed by KCZ in the same fash-
ion as the forskolin stimulated adenylate cyclase activity
(Table 2).
In summary, our data suggested that KCZ inhibits cAMP
generation and progesterone biosynthesis at the direction of
the catalytic component of the adenylate cyclase holoenzyme
in MA-10 mouse Leydig tumor cells.
REFERENCES
1) Couch R. M., Muller J., Perry Y. S., Winter J. S. D., J. Clin. En-
docrinol. Metab., 65, 551—554 (1987).
2) Dunbar M., Pyle R. L., Boring J. G., McCoy P., JAVMA, 182, 156—
157 (1983).
3) Medleau L., Chalmers S. A., JAVMA, 201, 1891—1892 (1992).
4) Nashan D., Knuth U. A., Weidinger G., Nieschlag E., Acta Endocrinol.
(Copenh.), 120, 677—681 (1989).
5) Sharp N. J. H., Sullivan M., JAVMA, 194, 783—786 (1989).
6) Willard M. D., Nachreiner R., McDonald R., Roudebush P., Am. J. Vet.
Res., 47, 2504—2509 (1986).
7) Van den Bossche H., Willemsens G., Cools W., Antimicrob. Agents
Chemother., 17, 922—928 (1980).
8) Pont A., Williams P. L., Loose D. S., Feldman D., Reitz R. E., Bochra
C., Stevans D. A., Ann. Intern. Med., 97, 370—372 (1982).
9) Pont A., Williams P. L., Azhar S., Reitz R. E., Bochra C., Smith E. R.,
Stevens D. A., Arch. Intern. Med., 142, 2137—2140 (1982).
10) Irsy G., Koranyi L., Acta Endocrinol. (Copenh.), 122, 409—413
(1990).
11) Kowal J., Endocrinology, 112, 1541—1543 (1983).
12) Bhasin S., Sikka S., Fielder T., Sod-Moriah U., Levine H. B.,
Swerdloff R. S., Rajfer J., Endocrinology, 118, 1229—1232 (1986).
13) De Coster R., Beerens D., Dom J., Willemsens G., Acta Endocrinol.
796 Vol. 25, No. 6
Table 2. Effect of KCZ on Forskolin and Sodium Fluoride Stimulated





Forskolin (5 mM) 2.9260.24*,a 399613*,b
Forskolin1KCZ (20 mM) 0.4260.11a 27069b
Basal 0.7060.08 19564
Sodium fluoride (1mM) 2.1360.21*,c 331620*,d
Sodium fluoride1KCZ (20 mM) 0.2460.07c 229613d
MA-10 cells were incubated 24 h. Different compounds were added to selected wells
and aliquots of the medium were removed from well at 2 h. Progesterone in the medium
was measured by enhanced chemiluminescent detection. cAMP in the medium was
measured by EIA. Each data in the table represents mean6S.E. of progesterone and
cAMP production of repeated experiments with triplicates in each treatment. Asterisk
( * ) indicates statistically significant difference (p,0.05) as compared with control
(without KCZ pretreatment) levels. Different letters beside the values indicates statisti-
cally significant difference (p,0.05) among treatments.
(Copenh.), 107, 275—281 (1984).
14) Lacoste D., St-Arnaud R., Caron S., Belanger A., Labrie F., J. Steroid
Biochem., 31, 963—970 (1988).
15) Pont A., Graybill J. R., Craven P. C., Galgiani J. N., Dismukes W. E.,
Reitz R. E., Stevens D. A., Arch. Intern. Med., 144, 2150—2153
(1984).
16) Santen R. J., Van den Bossche H., Symoens J., Brugmans J., De Coster
R., J. Clin. Endocrinol. Metab., 57, 732—736 (1983).
17) Heyns W., Drochmans A., van der Schueren E., Willemsens G., Acta
Endocrinol., 110, 276—283 (1984).
18) Trump D. L., Havlin K. H., Messing E. M., Cummings K. B., Lange P.
H., Jordan V. C., J. Clin. Oncol., 7, 1093—1098 (1989).
19) Sonino N., Boscaro M., Merola G., Mantero F., J. Clin. Endocrinol.
Metab., 61, 718—722 (1985).
20) Saez J. M., Endocrino. Rev., 15, 574—626 (1994).
21) Ascoli M., Endocrinology, 108, 88—95 (1981).
22) Chaudhary L. R., Stocco D. M., Biochem. Int., 18, 251—262 (1989).
23) Van den Bossche H., Lauwers W., Willemsens G., Cools W., Prog.
Clin. Biol. Res., 185A, 187—196 (1985).
24) Sikka S. C., Swerdloff R. S., Rajfer J., Endocrinology, 116, 1920—
1925 (1985).
25) Rajfer J., Sikka S. C., Rivera F., Handelsman D. J., J. Clin. Endocrinol.
Metab., 63, 1193—1198 (1986).
26) Loose D. S., Kan P. B., Hirst M. A., Marcus R. A., Feldman D., J. Clin.
Invest., 71, 1495—1499 (1983).
27) Kan P. B., Hirst M. A., Feldman D., J. Steroid Biochem., 23, 1023—
1029 (1985).
28) Cronin M. J., Evans W. S., Rogol A. D., Weiss A. A., Thorner M. O.,
Orth D. N., Nicholson W. E., Yasumoto T., Hewlett E. L., Am. J. Phys-
iol., 251, 164—171 (1986).
29) Erneux C., van Sande J., Miot F., Cochaux P., Decoster C., Dumont J.
E., Mol. Cell. Endocrinol., 43, 123—134 (1985).
30) Cronin M. J., Hewlett E. L., Evans W. S., Thorner M. O., Rogol A. D.,
Endocrinology, 114, 904—913 (1984).
June 2002 797
